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Cancer cells must integrate multiple biosynthetic
demands to drive indefinite proliferation. How these
key cellular processes, such as metabolism and pro-
tein synthesis, crosstalk to fuel cancer cell growth is
unknown. Here, we uncover themechanism bywhich
the Myc oncogene coordinates the production of
the twomost abundant classes of cellular macromol-
ecules, proteins, andnucleic acids in cancer cells.We
find that a single rate-limiting enzyme, phosphoribo-
syl-pyrophosphate synthetase 2 (PRPS2), promotes
increased nucleotide biosynthesis in Myc-trans-
formed cells. Remarkably, Prps2 couples protein
and nucleotide biosynthesis through a specialized
cis-regulatory elementwithin thePrps2 50 UTR,which
is controlled by the oncogene and translation initi-
ation factor eIF4E downstream Myc activation. We
demonstrate with a Prps2 knockout mouse that the
nexus between protein and nucleotide biosynthesis
controlled by PRPS2 is crucial for Myc-driven tumor-
igenesis. Together, these studies identify a transla-
tionally anchored anabolic circuit critical for cancer
cell survival and an unexpected vulnerability for
‘‘undruggable’’ oncogenes, such as Myc.INTRODUCTION
The ability to alter metabolic output to fulfill the biosynthetic
and bioenergetic demands of cell growth and proliferation is
a defining feature of cancer cells (Cairns et al., 2011; Vander
Heiden et al., 2011; Ward and Thompson, 2012). For example,
the Myc oncogene reprograms several cellular machineries,
including those promoting protein synthesis, glycolysis, glutami-
nolysis, and nucleotide synthesis, all of which are vital for sus-
taining cancer cell survival (Dang, 2010; Gordan et al., 2007;
Liu et al., 2008; Mannava et al., 2008; Morrish et al., 2008;
Wise et al., 2008). An outstanding question is how cancer cells
couple multiple macromolecular synthetic processes to sustain1088 Cell 157, 1088–1103, May 22, 2014 ª2014 Elsevier Inc.an enhanced bioenergetic homeostasis vital for cancer cell
survival. For instance, cancer cells need to maintain a careful
homeostasis between the rate of protein biosynthesis and the
metabolic flux that supplies the biosynthetic precursors and en-
ergy necessary for cancer cell growth and survival. In particular,
the increased rate of protein synthesis that sustains cancer cell
growth upon Myc hyperactivation imposes an onerous biosyn-
thetic and bioenergetic cost to cancer cells (Bywater et al.,
2013; Granneman and Baserga, 2004; Lempia¨inen and Shore,
2009; White, 2008). Therefore, an unanswered question is how
key cellular processes underlying cancer cell growth, such as
metabolism and protein synthesis, become coordinated and
are maintained, and whether this point of intersection reflects a
unique vulnerability that could be targeted. This question is
particularly critical, as the Myc oncogene, at present, remains
‘‘undruggable.’’
In this work, we employed amultifaceted approach integrating
metabolomics with a unique mouse genetic strategy to address
how production of two of the most abundant classes of cellular
macromolecules, proteins and nucleic acids, are integrated and
coupled by the Myc oncogene. Surprisingly, we find that Myc-
driven hyperactivation of protein synthesis stimulates the trans-
lational upregulation of one key rate-limiting enzyme, PRPS2,
within the nucleotide biosynthesis pathway. Many translationally
regulated transcripts downstream of mTOR hyperactivation
harbor a pyrimidine-rich translational element (PRTE) positioned
within their 50 UTR (Hsieh et al., 2012). Interestingly, we find that
Prps2 contains a PRTE that enables translational regulation by
Myc to directly increase nucleotide biosynthesis proportionately
to the increasedprotein synthesis rates of cancer cells. Strikingly,
PRPS1, a related isoform that is responsible for widespread ef-
fects on nucleotide metabolism in normal cells, lacks the PRTE
cis-regulatory translational element within its 50 UTR, thereby
revealing a distinguishing feature of an isoform-specific PRPS
in cancer cells. Therefore, these findings delineate a self-regu-
lating circuitry through which cancer cells ensure balanced coor-
dination between the production of proteins and nucleic acids.
Importantly, by specifically inhibiting expression of Prps2, we
demonstrate synthetic lethality in Myc-overexpressing cells and
dramatically decreased tumorigenic potential in vivo, illuminating
an important vulnerability and therapeutic window for cancers
driven by ‘‘undruggable’’ oncogenes, such as Myc.
RESULTS
Elevated Rates of Protein Synthesis Sustain the Myc-
Dependent Metabolic Program
It remains unknown whether and how the elevated metabolic
and protein synthesis programs of cancer cells are sensed and
coupled to promote cancer cell growth and development. We
first sought to genetically determine whether Myc’s ability to
increase the protein synthetic capacity of cancer cells is directly
linked to enhanced metabolism. The Em-Myc/+ transgenic
mouse faithfully recapitulates the clinical features of human Bur-
kitt’s lymphoma (Adams et al., 1985; Harris et al., 1988). B cells
derived from these mice display a dramatic increase in Myc-
dependent ribosome biogenesis and protein synthesis, resulting
in increased cell growth, which is a hallmark of Myc-driven can-
cers (Barna et al., 2008; Iritani and Eisenman, 1999). Previous
studies have revealed that haploinsufficiency of a single
ribosomal protein (RP), RPL24, leads to an overall decrease
in protein synthesis and that RPL24 haploinsufficiency in the
Em-Myc/+ genetic background is sufficient to restrain Myc-
dependent hyperactivation of protein synthesis to normal levels,
dramatically thwarting Myc’s oncogenic activity (Barna et al.,
2008). Therefore, we reasoned that Em-Myc/+;Rpl24BST/+ mice
represent an ideal genetic tool to assess the functional relation-
ship between Myc-dependent increases in protein synthesis
rates and cancer cell metabolism.
We employed unbiased nuclear magnetic resonance (NMR)-
based metabolomics to compare and measure the steady-state
metabolite concentrations in freshly isolated Em-Myc/+ and Em-
Myc/+;Rpl24BST/+B cells, where elevated protein synthesis rates
are restored to normal, aswell as respective, controls (Figure 1A).
Consistent with an overall shift in metabolic processes to an
anabolic state, we find that Myc-overexpressing cells, both in
the pretumor and in the tumor setting, display an overall deple-
tion in formate, acetate, and propionate, which are used for the
construction of larger, more complex metabolites, such as nu-
cleotides, lipids, and amino acids (Figure 1B). We also find that
in the pretumor setting, Myc broadly increases the levels of
metabolites frequently found increased in cancer cells, such as
purine nucleotides, choline, phosphocholine, acetylcarnitine,
and several amino acids, such as glycine and proline (Figure 1B).
However, there also appears to be cell-type specificity. For
example, the levels of glutamine or lactate previously linked to
Myc-dependent metabolism are not altered in Em-Myc/+ B cells
(Wise et al., 2008; Yuneva et al., 2012). The changes observed in
the pretumor setting are maintained and, in most cases, ampli-
fied in the Myc-driven malignant lymphoma setting.
We directly ascertained how elevated protein synthesis rates
in cancer influence the cancer metabolome. Strikingly, in Em-
Myc/+;Rpl24BST/+ B cells, we observed a specific rescue in a
subset of metabolites normally found elevated in Em-Myc/+ cells.
Unexpectedly, the most notable class of such metabolites is
the nucleotides IMP, AMP, ADP, and ATP (Figures 1B and 1C,
inset). The observed rescue in nucleotide metabolite production
in Em-Myc/+ compared to Em-Myc/+;Rpl24BST/+ B cells was also
further validated by high-performance liquid chromatography
(HPLC) (Figure S1A available online) and a PCR-based assay
to measure free dNTP concentrations from a complex mixtureof intracellular metabolites (Figure S1B). Together, these find-
ings suggest that augmented protein biosynthesis may be
directly coupled to the control of nucleotide metabolism down-
stream of Myc hyperactivation, revealing an unexpected coordi-
nation between the production of the two most abundant
classes of macromolecules in cancer cells: proteins and nucleic
acids.
PRPS2 Is a Critical Rate-Limiting Enzyme-Integrating
Myc-Dependent Protein Synthesis with Nucleotide
Metabolism
Elevated nucleotide pools, through either de novo synthesis
from carbohydrate and amino acid precursors or by salvage
enzymes that rejoin recycled nucleobase and sugar moieties,
are a defining feature of many cancer cells, required to carry
out a diverse array of cellular functions (Tong et al., 2009). The
effect of Myc on nucleotide levels is due, in large part, to
increases in rates of de novo purine biosynthesis as revealed
by the increased incorporation of radiolabeled precursors
([14C]-formate) for the de novo synthesis pathway (Figure 1D).
Our findings also show thatMyc increases nucleotide production
by promoting flux through the purine salvage pathway (Fig-
ure 1E). Overall, these experiments suggest that Myc-depen-
dent control of purine nucleotide concentrations relies on the
increased biosynthetic production of purine precursors.
We next asked whether Myc-dependent increases in protein
synthesis influence the expression of one or several key en-
zymes upstream or within the purine biosynthetic pathway.
We identified a critical rate-limiting enzyme of purine biosyn-
thesis, phosphoribosyl-pyrophosphate synthetase 2 (PRPS2),
as a translationally regulated mRNA whose protein levels are
increased upon Myc overexpression and restored to wild-type
(WT) levels in Em-Myc/+;Rpl24BST/+-derived B cells (Figures 1F
and 1G). This effect on posttranscriptional control of Prps2 is
highly specific as, notably, other important enzymes involved
in nucleotide metabolism are expressed similarly in Em-Myc/+
and Em-Myc/+;Rpl24BST/+ B cells (Figures 1F, 1G, and S1C).
Therefore, these results unexpectedly suggest that one key
enzyme within the purine biosynthesis pathway may be directly
coupled to increased rates of protein synthesis elicited by the
Myc oncogene to further regulate the flow of metabolic interme-
diates through the entire nucleotide pathway.
Phosphoribosyl pyrophosphate synthetase (PRPS) activity
plays a central metabolic role in the production of nucleotides.
The PRPS enzyme adds a pyrophosphate group donated from
ATP to ribose-5-phosphate generated from the pentose phos-
phate pathway to produce 5-phosphoribosyl-1-pyrophosphate
(PRPP) (Figure 2A). PRPP is a substrate for all nucleotide salvage
pathway enzymes, as well as the rate-limiting enzymes of purine
and pyridine biosynthesis. Because the KM rate constants of
nucleotide biosynthetic pathway enzymes that utilize PRPP as
a substrate far exceed the physiological intracellular concentra-
tions of this metabolite, an increase in PRPP levels may be
sufficient to govern the overall nucleotide biosynthetic rate of
cells. Therefore, we next addressed whether PRPS2 as a single
enzyme is necessary and sufficient to control the overall purine
biosynthesis and salvage rates of cells. To this end, we directly
modulated Prps2 expression levels in freshly isolated primaryCell 157, 1088–1103, May 22, 2014 ª2014 Elsevier Inc. 1089
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B cells (Figures 2B, 2C, and S2A). Upon knockdown of Prps2
expression in primary B cells using small interfering RNA (siRNA)
(Figures 2B and S2A), we observed a 14%decrease in the rate of
[14C] formate incorporation into purines compared to control
siRNA-transfected cells (Figures 2D and 2E), demonstrating
the requirement of PRPS2 enzymatic activity for the optimum
rate of de novo purine biosynthesis. Conversely, overexpression
of Prps2 in B cells caused a 21% increase in [14C] formate incor-
porated into purine nucleotides (Figure 2F). To assess the contri-
bution of PRPS2 activity toward nucleotide salvage pathway
function, we measured [8-14C] hypoxanthine labeling of purines
upon knockdown or overexpression of Prps2 in B cells (Fig-
ure 2G). Although less dramatic than the effect observed on
de novo purine biosynthesis, both knockdown (Figure 2H) and
overexpression (Figure 2I) resulted in significant decreases or in-
creases, respectively, in [14C] incorporation. Therefore, PRPS2
levels are rate limiting and important for controlling nucleotide
biosynthesis rates, revealing a key enzyme that promotes nucle-
otidemetabolism and is regulated at the posttranscriptional level
by Myc hyperactivation.
Prps2, but not Prps1, Gene Expression Is Regulated
Acutely at the Translational Level
Given the critical importance of PRPS2 protein levels in purine
metabolic flux, we hypothesized that translational control of
Prps2 gene expression may serve at the interface of protein
and nucleotide biosynthesis control. To address whether
translational control of Prps2 may provide a rapid and dynamic
mechanism to regulate purine synthesis, we acutely and
rapidly induced mitogen-dependent protein synthesis in
serum-starved cells by 30 min of serum stimulation (Geyer
et al., 1982). Strikingly, the levels of PRPS2 protein, but not
mRNA, increased dramatically upon addition of serum, sug-
gesting that Prps2 may be regulated at the translation level
(Figures 3A and 3B). To test this hypothesis, we employed
ribosome sucrose-gradient fractionation. Indeed, upon 30 min
of serum stimulation, we observe an increase in the amount
of Prps2 mRNA associated with heavy polyribosomes frac-
tions, containing highly translating mRNAs, compared to
serum-starved cells (Figures 3C and 3D). Moreover, Prps2
showed the same acute translational activation as other growth
factor-responsive genes, such as Ribosomal Protein S3 (Rps3),
a bona fide translationally regulated mRNA, and c-Myc (Figures
S3A–S3C), that respond immediately and rapidly to acute
serum stimulation.Figure 1. Unbiased Metabolomics Approach Reveals Myc-Dependent
(A) Genetic approach to identify translationally regulated metabolites downstrea
(B) Intracellular steady-state metabolite profiles of B cells isolated fromWT, Em-M
tumor-bearing mice.
(C) Representative 1H NMR spectra of extractedmetabolites from B cells with (ins
purine profiles from indicated genotypes.
(D) Metabolic flux through de novo purine synthesis pathway measured by [14C]
(E) Metabolic flux through purine salvage pathway measured by [8-14C] hypoxan
(F)Western blot analysis of indicated nucleotide biosynthesis enzymes fromwhole
Em-Myc/+;Rpl24BST/+ mice.
(G) Quantitative real-time PCR analysis of mRNA levels of indicated enzymes fro
Error bars represent SD; n = 6 for (D) and (E); n = 4 for (G). ***p < 0.001, **p < 0.0Notably, although there are two isoforms of PRPP synthe-
tase expressed in somatic tissues, only Prps2, and not
Prps1, displays increased translation upon serum stimulation
(Figure 3C). Interestingly, the PRPS2 isoform is largely resis-
tant to feedback inhibition by the nucleotide biosynthesis
products ADP and GDP that is a feature of the PRPS1 enzyme
(Nosal et al., 1993). This enzymatic property of PRPS2 may
facilitate the unrestrained, elevated production of nucleotides
observed in Myc-overexpressing cells, as well as explain
why the levels of PRPS2, but not PRPS1, are increased in
cancer cells. The translational regulation of Prps2 is highly
specific, as other members of the purine biosynthetic pathway
are not regulated in this manner (Figure 3A). Therefore, trans-
lational control of Prps2 is a rapid sensor of the total rate of
protein biosynthesis within the cell, which precedes biomass
accumulation.
Prps2 Translation Is Controlled by the eIF4E Oncogene
through a Conserved cis-Acting Regulatory Element
that Directs Nucleotide Production
An unresolved question is how Prps2, but not other members of
the purine biosynthesis pathway, is specifically and acutely regu-
lated at the translation level downstream of Myc hyperactivation.
Progrowth signals, such as serum stimulation and Myc hyperac-
tivation, are thought to regulate translation of specific subsets of
mRNAs through increases in the activity of themajor cap-binding
protein, eIF4E (Hsieh and Ruggero, 2010; Ruggero et al., 2004;
Topisirovic and Sonenberg, 2011). Importantly, eIF4E is also a
direct transcriptional target of Myc (Jones et al., 1996) and is
a master regulator of the rate-determining step in translation
initiation. Upon forced overexpression of Myc, we also observe
an increase in eIF4E levels that coincides with elevated Prps2
expression (Figures S3D and S3E). Therefore, using specific
inhibitors that target the activity of eIF4E, we tested whether
the effects of Prps2 translational control are mediated through
eIF4E hyperactivation. Specifically, we pretreated serum-
starved fibroblasts with either an mTOR active-site inhibitor
(MLN0128), which blocks the phosphorylation of eIF4E binding
protein 1 (4EBP1), or with a MEK1/2 inhibitor (PD901), which im-
pairs eIF4E phosphorylation. Notably, in both of these treat-
ments, we observe that the increases in PRPS2 protein levels
present upon acute serum stimulation are abolished (Figures
3E and 3F).
To extend our findings demonstrating eIF4E-mediated transla-
tional control of Prps2 mRNA in vivo, we employed a geneticTranslational Control of Purine Nucleotide Levels
m of oncogenic Myc in B cells.
yc/+ premalignancy, Rpl24BST/+ (L24+/), Em-Myc/+;Rpl24BST/+, and Em-Myc/+
et) zoomed-in view of region between 8.52–8.61 ppm containing representative
formate incorporation in WT and Em-Myc/+-derived B cells.
thine incorporation in WT and Em-Myc/+-derived B cells.
-cell lysates of B cells derived from 5-week-oldWT, Em-Myc/+,Rpl24BST/+, and
m mRNA levels of indicated genes in B cells of mice as in (F).
1, *p < 0.05 by Student’s t test. See also Figure S1.
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Figure 2. PRPS2 Is a Rate-Limiting Enzyme for Purine Synthesis and Salvage Pathways
(A) Schematic of the pathway of PRPP biosynthesis produced from glucose.
(B) Western blot of primary WT B cells transduced with control or Prps2 siRNA.
(C) Western blot of primary WT B cells mock transfected or transfected with capped, polyadenylated FLAG-Prps2 encoding mRNA.
(legend continued on next page)
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system to specifically express a doxycycline-inducible domi-
nant-negative eIF4E binding protein 1 (DN-4EBP1) transgene in
B cells (Figure 4A) (Hsieh et al., 2010; Pourdehnad et al., 2013).
This genetic strategy neither perturbs global protein synthesis
nor cell viability but rather only affects the translation of eIF4E
rate-limiting target mRNAs (Hsieh et al., 2010). The inducible
downregulation of eIF4E activity decreased expression of
PRPS2 protein (Figure 4B) without affecting Prps2 mRNA levels
(Figure S4A). Importantly, eIF4E-dependent translational control
within the nucleotide biosynthesis pathway is selective for Prps2
as the expression levels of additional key enzymes in this
pathway, such as IMPDH2, PPAT, and ATIC, remain unchanged
in DN-4EBP1 transgenic mice (Figure 4B). c-Myc expression
is also unaffected by inhibition of eIF4E in Em-Myc/+-derived
B cells (Pourdehnad et al., 2013). We next intercrossed
Em-Myc/+ transgenic mice with inducible DN-4EBP1 transgenic
mice. In Em-Myc/+;DN-4EBP1T mice, PRPS2 abundance is
restored to WT levels within 6 hr of DN-4EBP1 expression
without affecting the Myc-dependent increases in Prps2 mRNA
levels or the expression of other key nucleotide biosynthetic
pathway enzymes (Figures 4C and S4B). These results demon-
strate that eIF4E-mediated translational activity is selectively
required for the Myc-dependent increase in total PRPS2 protein
levels observed in Em-Myc/+ B cells.
We next tested whether a specific sequence or motif could be
responsible for the translational regulation of Prps2. A recently
identified, important eIF4E cis-regulatory element that confers
translational specificity is the pyrimidine-rich translational
element (PRTE) (Hsieh et al., 2012). Consistent with our findings
thatPrps2, and not Prps1, is regulated at the level of translational
control, only Prps2 contains a consensus PRTEmotif within its 50
UTR (Figure S4C). To test the possibility that Prps2 displays dif-
ferential sensitivity to translational regulation by eIF4E, we con-
structed luciferase reporter constructs fused to the 50 UTR of
Prps1 and Prps2, as well as deletion and transversion mutants
of the PRTE domainwithinPrps2. Strikingly, transfection of these
reporter constructs revealed that the PRTE motif is sufficient to
direct translational control of Prps2 in an eIF4E-dependent
manner and that the related PRPS1 isoform is not regulated by
thismode of translational control (Figures 4D andS4D). Addition-
ally, theWT Prps2 50 UTR luciferase reporter was selectively acti-
vated in Myc-overexpressing cells, whereas the Prps2 50 UTR
PRTE deletion reporter and Prps1 50 UTR reporter were not (Fig-
ure 4E), therefore confirming the direct link between Myc-over-
expression and increased Prps2 gene expression through a
unique eIF4E-dependent cis-acting regulatory element. Impor-
tantly, other genes of the nucleotide biosynthesis pathway lack
this functional motif within their 50 UTRs (data not shown; Fig-
ure S4C). Thus, Prps2 possesses a functional translational
enhancer element within its 50 UTR that may act as a critical(D) Schematic illustrating [14C] formate incorporation into the de novo purine bio
(E) Measurement of [14C] formate incorporation into purines from cells treated as
(F) Measurement of [14C] formate incorporation into purines from cells treated as
(G) Schematic illustrating [8-14C] hypoxanthine incorporation into purines via the
(H) Measurement of [8-14C] hypoxanthine incorporation into purines from cells tr
(I) Measurement of [8-14C] hypoxanthine incorporation into purines from cells tre
For all graphs, error bars represent SD; n = 6; **p < 0.01, *p < 0.05 by Student’sbottleneck in the production of nucleotides in cancer that is
coupled to protein synthesis.
To furtherdefine theprecise contributionof translational control
of Prps2 toward nucleotide biosynthesis, we employed fibro-
blastsderived fromPrps2nullmice (see Figures 6 andS6 for details
regarding generation of Prps2null mice). We transfected mRNAs
encoding FLAG-PRPS2 fused to either the WT 50 UTR of Prps2
or the 50 UTR of Prps2 engineered to lack the pyrimidine-rich
translational element (DPRTE), which confers sensitivity to
eIF4E-mediated translation control. Importantly, only Prps2null
cells transfected with the Prps2 50 UTR, FLAG-PRPS2, but not
the DPRTE 50 UTR mutant, displayed a serum-dependent in-
crease in translation of FLAG-PRPS2 protein and increased pu-
rine nucleotide production (Figures 4F and 4G). Therefore, the
PRTE sequence in Prps2 mRNA acts as a dynamic sensor that
couples protein biosynthesis with nucleotide production.PRPS2 Knockdown Is Synthetically Lethal in
Myc-Overexpressing Cells and Blocks Myc-Dependent
Tumor Initiation and Maintenance In Vivo
We tested whether inhibiting translational regulation of Prps2
mRNA could represent a potential synthetic lethal interaction
with Myc hyperactivation. We observe a dramatic increase in
Prps2 translation upon oncogenic cellular transformation driven
by Myc and Ras that relies on eIF4E activity, demonstrating that
translational regulation of Prps2 occurs as an early event during
oncogenic transformation (Figure 5A). This is consistent with the
upregulation in PRPS2 protein during the early pretumor stage of
Myc-driven lymphomagenesis (Figure 1F). Next, to directly
address the functional relevance of increased Prps2 expression
in cellular transformation, we performed knockdown of Prps2 in
Ras andMyc-transformed MEFs. Strikingly, we observed a 70%
increase in apoptosis upon Prps2 knockdown in transformed,
but not WT, cells (Figure 5B). Importantly, this increase in
apoptosis was specific to the knockdown of the PRPS2 isozyme,
as knockdown of PRPS1 did not affect cellular viability in normal
or transformed MEFs (Figures 5B and S5A).
We next wanted to address why PRPS2 loss, but not PRPS1
loss, is deleterious for the viability of Myc-overexpressing trans-
formed MEFs. Whereas siRNA-mediated knockdown of either
PRPS2 or PRPS1 led to only a modest decrease in purine nucle-
otide production in WT MEFs, knockdown of PRPS2, but not
PRPS1, resulted in a dramatic decrease in purine nucleotide pro-
duction in MEFs transformed by Myc and Ras overexpression
(Figure S5B). Additionally, knockdown of PRPS1 or PRPS2 in
WT MEFs produced similar decreases in the rates of RNA and
DNA production (Figures S5C and S5D). These results suggest
that, whereas PRPS2 and PRPS1 play interchangeable roles in
normal cells, Myc-overexpressing cancer cells rely on the spe-
cific activity of PRPS2 to produce the nucleotides necessary tosynthesis pathway.
in (B).
in (C).
HPRT nucleotide salvage enzyme.
eated as in (B).
ated as in (C).
t test. See also Figure S2.
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sustain their metabolic demands. Because Myc overexpression
is known to sensitize cells to apoptosis, loss of function of
PRPS2 may exacerbate the apoptotic program normally regu-
lated by Myc. To test this possibility, we generated cells that
overexpress apoptosis-resistant Myc amino acid substitution
mutant alleles (Graves et al., 2010; Hemann et al., 2005). Each
mutant tested (P57S, F138C, and T58A) was able to increase
the expression of the nucleotide biosynthetic pathway enzymes
PPAT, UMPS, and PRPS2 to similar degrees (Figure 5C) and,
importantly, retained the sensitivity to programmed cell death
induced by PRPS2 knockdown (Figure 5D). Taken together,
these results suggest that loss of function of PRPS2 does not
simply augment the apoptotic program already regulated by
Myc but rather disrupts the Myc-dependent metabolic program
in cancer cells, leading to synthetic lethality.
We next tested the potential therapeutic effects of PRPS2
knockdown in vivo. We observe a 40% induction of apoptosis
(Figure 5E) inMyc-overexpressing B cells, but not in normal cells,
upon PRPS2 knockdown in a pretumor setting. Upon induced
expression of Prps2 short hairpin RNA (shRNA) in vivo, we also
observed an increase in apoptosis of Myc-expressing cells
within the tumor setting (Figures 5F and 5G). Notably, mice
induced to express shRNA directed toward Prps2 showed a sig-
nificant delay in Myc-driven tumor onset (Figure 5H). We next
assessed the therapeutic efficacy of PRPS2 loss of function in
established Myc-driven lymphomas. After tumor formation,
Prps2 shRNA expression was induced and tumor progression
was monitored (Figures 5I and S5F). We observed a strong
impairment in tumor progression upon knockdown of Prps2,
and remarkably, at least 30% of these mice displayed complete
tumor regression and survival beyond 7months of age, revealing
a critical oncogenic role of PRPS2.
Generation of a Prps2 Knockout Mouse Reveals that
PRPS2 Is Dispensable for Normal Physiology and
Cellular Function but Is Required for Metabolic
Homeostasis in Myc-Overexpressing Cells
A remaining question is whether PRPS2 is normally essential for
cell and organismal physiology in vivo. To address this question,
we generated a Prps2 knockout mouse (Figure S6A). Strikingly,
mice homozygous null for the Prps2 gene (Prps2null) are viable
and fertile and display no gross phenotypic abnormalities,
despite lacking Prps2 mRNA and protein expression (Figures
S6BandS6C).Notably, therewasnocompensatory upregulation
of Prps1 mRNA levels in tissues from Prps2null mice, suggestingFigure 3. Prps2 mRNA Is Regulated Acutely at the Translational Level
(A) Western blot (WB) of indicated purine biosynthesis enzymes from serum-star
(B) Quantitative real-time PCRmeasurement of mRNA levels of indicated genes fr
bars represent SD.
(C) Polysomal analysis of Prps2 and Prps1 mRNA in cells treated as in (A). The p
titative real-time PCR analysis in each fraction normalized to the correspondin
represent SD; n = 4; *p < 0.05 by Student’s t test.
(D) Polysome profiles of serum-starved and serum-stimulated NIH 3T3 cells tre
minutes.
(E) WB of serum-starved NIH 3T3 cells treated for 30 min with 20% FBS or 20%
MLN0128.
(F) WB of serum-starved NIH 3T3 cells treated for 30 min with 20% FBS or 20%
See also Figure S3.that normal expression levels and enzymatic activity of PRPS1
are sufficient to maintain metabolic homeostasis (Figure S6C).
As the critical nucleotide biosynthetic intermediate, PRPP is
only produced by PRPS enzymes; these findings are consis-
tent with the continued activity of the PRPS1 isozyme, whose
mRNA is interestingly normally found expressed at higher levels
than Prps2 in all tissues we surveyed (Figures S6C and S6D).
We next investigated the function of PRPS2 in normal B cell
homeostasis. In Prps2null mice, Prps1 expression in splenic B
cells was maintained at the same levels observed in WT cells
(Figures 6A and 6B). Complete loss of Prps2 expression did
not alter spleen weight, tissue architecture, or morphology (Fig-
ures 6C, 6D, and S6E). Moreover, the percent of B lymphocytes
present in the spleen (Figure 6E), as well as B cell size (Fig-
ure S6F), cell-cycle distribution (Figure S6G) or cell viability (Fig-
ure S6H), was not altered. Although Prps2null B lymphocytes
display no overt phenotypic differences, they do have a minor
decrease in rates of purine nucleotide biosynthesis, which are
further decreased upon siRNA-mediated knockdown of the
PRPS1 isozyme (Figure 6F). Together, these results suggest
that the activity of PRPS1 alone is sufficient to maintain the
normal function of B lymphocytes and spleen development,
whereas PRPS2 function is dispensable.
As PRPS2 shares 95% amino acid identity with the PRPS1
isoform (Becker et al., 1990), it remains unknownwhether cancer
cells have evolved a mechanism to promote cell survival through
only one of the two PRPS isoforms. To address this question, we
utilized Prps2null MEFs engineered to overexpress a ligand-acti-
vatableMycER allele (Eilers et al., 1989). Notably, treatment with
4-hydroxytamoxifen to activate Myc increased only PRPS2,
but not PRPS1, protein abundance (Figure 6G). Strikingly, our
data demonstrate that the Myc-dependent increase in the
purine nucleotide production rate can be completely restored
to WT levels in Em-Myc/+;Prps2null B cells (Figure 6H). Therefore,
these results suggest a specific requirement for PRPS2, but not
PRPS1, function in maintaining the metabolic homeostasis of
Myc-overexpressing cells.
We then sought to determine the most immediate effects of
nucleotide production driven by PRPS2 downstream of Myc hy-
peractivation. An increased pool of RNA nucleotides is utilized by
cancer cells for incorporation into rRNA and tRNA to generate
increased numbers of ribosomes (Ben-Sahra et al., 2013).
In addition, sufficient pools of deoxyribonucleotides are also
required to maintain DNA fidelity during replication (Bester
et al., 2011) and to bypass oncogene-induced senescenceved or 30 min fetal bovine serum (FBS)-stimulated NIH 3T3 cells.
om cells treated as in (A). Data are normalized to b-actinmRNA levels, and error
olysomal association of Prps2 mRNA measuring mRNA abundance by quan-
g 5S rRNA levels and expressed as a fraction of the total mRNA. Error bars
ated as in (A) plotted as relative absorbance at 254 nm versus elution time in
FBS after a 10 min pretreatment with 100 nM of the mTOR active-site inhibitor
FBS after a 10 min pretreatment with 100 nM of the MEK1/2 inhibitor PD901.
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Figure 4. Prps2 mRNA Translation, but Not Prps1, Is Regulated via a cis-Regulatory Motif in Its 50 UTR by the eIF4E Oncogene that Directs
Increases in Nucleotide Metabolism
(A) Compound transgenic mice generated to drive inducible expression of dominant-negative-4EBP1 (DN-4EBP1) specifically in B lymphocytes.
(B) Western blot (WB) of indicated purine biosynthesis enzymes from lysates of purified B cells frommice described in (A) treated by intraperitoneal (i.p.) injection
with vehicle or doxycycline for 6 hr. Arrow demarcates slower migrating transgenic DN-4EBP1 protein.
(C) WB of indicated purine biosynthesis enzymes from lysates of purified B cells in (A) in WT or Em-Myc/+ transgenic mice treated by i.p. injection with vehicle or
doxycycline for 3 or 6 hr. Arrow demarcates slower migrating transgenic DN-4EBP1 protein.
(legend continued on next page)
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(Aird et al., 2013). Importantly, in Em-Myc/+;Prps2null B cells, the
decrease in overall nucleotide production leads to overall de-
creases in the rate of ribo- and deoxyribo-nucleic acid produc-
tion compared to Myc-overexpressing B cells (Figures 6I and
6J). As total cellular RNA is predominantly comprised of ribo-
somal RNA, we next examined whether the augmented rates
of protein synthesis evident upon Myc hyperactivation are
altered in Em-Myc/+;Prps2null B cells. Indeed, our data demon-
strate that the overall rate of protein synthesis in Em-Myc/+ B
lymphocytes, but not in normal B cells, is decreased toward
normal levels in Prps2null mice (Figure 6K). Importantly, limiting
the protein synthetic capacity in Em-Myc/+ B cells by genetic
or pharmacological means has been previously shown to
promote increased programmed cell death (Barna et al., 2008;
Bywater et al., 2012). These findings suggest a possible mecha-
nism for the synthetic lethality observed in Myc-overexpressing
cells upon loss of PRPS2 function.
Interference with glucose metabolism has also been shown to
limit oncogenic potential or promote apoptosis in Myc-overex-
pressing cells (Doherty et al., 2014; Faubert et al., 2013; Shim
et al., 1998). Normal cells lacking PRPS2 display little to no differ-
ence in glucose uptake or in the rate of lactate production,
glucose oxidation, and glucose conversion to purines, RNA,
and DNA (Figures S7A–S7F). On the contrary, Em-Myc/
+;Prps2null B lymphocytes have increased glucose uptake
compared to Em-Myc/+ counterparts (Figures S7A), and glucose
oxidation occurs at a faster rate despite no alterations in overall
mitochondrial mass or mitochondrial membrane potential (Fig-
ures S7C, S7G, and S7H). Taken together, these experiments
suggest that Myc-overexpressing cells lacking PRPS2 are
thrown into ‘‘metabolic disarray’’ with perturbations in glucose
utilization, as well as the anabolic metabolism of nucleotides, nu-
cleic acids, and proteins, thereby hindering cancer cell survival.
PRPS2 Is Critical for Myc-Driven Cancer in Human and
Mouse Models
We employed Prps2null mice to directly genetically address the
requirement of PRPS2 activity in Myc-driven lymphomagenesis.
We first assessed the role of PRPS2 in the cellular function of
premalignant Em-Myc/+ B lymphocytes. Consistent with an
effect on Myc-overexpressing cell viability upon PRPS2 knock-
down, we observed a dramatic increase in apoptosis in
Em-Myc/+;Prps2null B lymphocytes (Figures 7A and 7B). To
investigate the therapeutic benefit that loss of function of
PRPS2 confers to Myc-driven lymphomagenesis, we carried
out a survival study. Em-Myc/+;Prps2null mice display a remark-
able delay in tumor initiation compared to their Em-Myc/+ litter-
mates, with approximately 60% of Em-Myc/+;Prps2null mice
that lived beyond 200 days, a time point at which almost all
Em-Myc/+mice had died (Figure 7C). To extend our observations
to human cancers, we employed two Burkitt’s lymphoma cell(D and E) Luciferase reporter assays of NIH 3T3 cells transfected with the indica
control empty vector (D) or transfected into stable NIH 3T3 cells expressing emp
(F) WB using indicated antibodies on lysates prepared fromWT or Prps2nullmouse
FLAG-PRPS2 encoded mRNAs treated with or without 1 hr serum stimulation. A
(G) [14C] formate incorporation into purine nucleotides was measured from cells
Error bars represent SD; n = 4; ***p < 0.001, **p < 0.01, *p < 0.05 by Student’s tlines, Daudi and Raji, and two Multiple Myeloma cell lines,
U266 and JJN-3, where Myc is found translocated and/or over-
expressed. Knockdown of PRPS2 in these Myc-dependent cell
lines resulted in a marked increase in apoptosis, revealing that
PRPS2 expression is required to sustain cancer cell survival in
bothmouse and human cancers that rely onMyc hyperactivation
(Figures 7D and S7I).
DISCUSSION
The Role of Translational Control in Cellular Metabolism
Our findings point to a model whereby translational regulation of
PRPS2 couples protein synthesis to metabolism and directly
acts as a molecular rheostat for the nucleotide biosynthesis
pathway in cancer cells, controlling the flow of ribose-5-phos-
phate from the pentose phosphate pathway into the nucleotide
biosynthetic precursor PRPP (Figure 7E). Therapeutic strategies
that interfere with this Myc-dependent translational control or
direct inhibition of PRPS2 expression create a ‘‘bottleneck’’
between the pentose phosphate pathway and nucleotide pre-
cursors to decrease the elevated nucleotide production that is
specifically required for cancer, but not for normal cell survival,
and consequently, tumor initiation and progression.
The ability to translationally up- or downregulate mRNAs that
encode enzymes capable of controlling metabolic flux ensures
a quick response to the protein synthesis demands of cancer
cells. Myc-overexpressing cells lacking PRPS2 have a reduced
capacity to increase protein synthesis, likely as a conse-
quence of the observed decrease in nucleotide production that
is required to synthesize ribosomes. Therefore, Myc-overex-
pressing cells establish a feedforward mechanism that tethers
increased protein synthesis rates to nucleotide production in
order to sustain their continued growth. In line with our findings,
restriction of either protein synthesis capacity or ribosome
biogenesis has been directly implicated as synthetically lethal
in Myc-overexpressing cells (Barna et al., 2008; Bywater et al.,
2012). The reliance of key oncogenes, such as Myc, on the post-
transcriptional regulation of PRPS2 reveals a significant vulnera-
bility to the maintenance of cancer cell homeostasis. In fact, our
data demonstrate that growth-factor-dependent increases in
Prps2 translation can be blocked by kinase inhibitors of mTOR
or MEK1/2, which converge on eIF4E activity. Therefore, the
identification of PRPS2 as a key, translationally regulated
enzyme may have broad implications for metabolic control in
many additional cancer types driven by distinct oncogenic sig-
nals, such as mTOR, where the translation of PRTE-containing
mRNAs are increased.
PRPS2 shares 95% amino acid identity with the PRPS1 iso-
form (Becker et al., 1990). However, our data demonstrate that
translational upregulation of PRPS expression by oncogenic sig-
nals occurs exclusively on the PRPS2 isozyme. Distinguishingted 50 UTR reporter constructs along with a DN-4EBP1 expression vector or
ty vector or Myc-pWZL (E).
embryo fibroblasts (MEFs) mock transfected or transfected with the indicated
rrow denotes ectopic FLAG-tagged PRPS2.
in (F).
test. See also Figure S4.
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biochemical features of the PRPS2 enzyme present intriguing
insight as towhy itmay be favored to promote nucleotide biosyn-
thesis in oncogenic cells. First, PRPS2 has been demonstrated
to be more resistant to the allosteric feedback inhibition
by nucleotide biosynthetic pathway byproducts ADP and GDP
(Nosal et al., 1993). This enzymatic property may allow PRPS2-
expressing cells to continue biosynthesis of nucleotides when
their intracellular concentrations are elevated. Additionally,
PRPS2 activity is more sensitive to fluctuations in the concentra-
tion of its substrate, ATP, which is present at elevated concentra-
tions in Myc-overexpressing B cells (Figures 1B and S1A) (Nosal
et al., 1993). These distinguishing enzymatic properties of the
different PRPS isoforms suggest a biochemical basis for the
development of specific inhibitors to selectively inhibit PRPS2.
PRPS2 as a Therapeutic Target
The Myc oncogene is currently undruggable. Because PRPS2
is an enzyme, it is considered part of the druggable genome
(Hopkins and Groom, 2002). Surprisingly, although loss of
expression of Prps2 resulted in a modest decrease in nucleotide
production in normal cells, there are no apparent deleterious
effects at the organismal level in Prps2null mice. Furthermore,
we show a therapeutic benefit upon loss-of-function of PRPS2
from the earliest stage of premalignancy through the later
stages of fully formed tumors, indicating that PRPS2-dependent
nucleotide production is an important, defining feature neces-
sary for cancer cell survival. Therefore, drugs capable of specif-
ically inhibiting the PRPS2 isoform may possess a selective
therapeutic window.
Inhibitors targeting the nucleotide biosynthetic pathway have
long been utilized as chemotherapeutic agents in the clinic.
However, many of these drugs produce significant toxicities
in widespread organs. Antifolates, which interfere with the one
carbon cycle, indiscriminately decrease nucleotide biosynthesis
in all proliferating tissues. Other drugs that specifically inhibit
the production of one of the five pyrimidine or purine nucleo-
tides disrupt the delicate balance within the nucleotide pools,
which leads to incorporation of improper bases into the geneticFigure 5. Loss of Function of PRPS2 Is Synthetically Lethal for Cancer
In Vivo
(A) Western blot (WB) analysis of indicated proteins in lysates from normal or trans
denotes sample with replenished media lacking doxycycline.
(B) Indicated cells were transfected with control, Prps1, or Prps2 siRNA, and apop
Annexin V+/Propidium iodide+ (PI) population in Prps1 or Prps2 siRNA-transfecte
(C) WB of lysates from stable NIH 3T3 cells expressing the indicated Myc WT or
enzymes.
(D) Cells from (C) were transfected with control or Prps2 siRNA and 48 hr later s
(E) WT or Em-Myc/+-derived B lymphocytes were isolated and transduced with p
Prps2 shRNA. Forty-eight hours posttransduction, cells were stained for Annexin
(F) WB of lysates prepared from B cells isolated frommice transplanted with Em-M
(G) Percent apoptotic cells represent Annexin V/PI+ percentage of GFP+ B lymp
(H) Fetal liver-derived Em-Myc/+ hematopoietic stem cells were transduced wit
inducible shRNA-targeting Prps2 and subsequently transplanted to lethally irrad
nodes between cohorts of mice.
(I) Em-Myc/+ tumor cells were isolated from a lymphoma-bearing mouse, trans
transplanted into syngeneic mice. Survival curves begin at start of treatment regim
data in graphs represent percent increase in Annexin V+/PI+ upon Prps1/2 siRN
For all experiments, error bars represent SD and n = 4 for (B), (D), and (E), and n =
Figure S5.code and results in DNA damage and/or defective gene
expression. Our data demonstrating that PRPS2 is a central
integrator of the two most abundant classes of macromolecules
comprising cells—proteins and nucleic acids—strongly sug-
gests a distinct therapeutic window exploiting the synthetic
lethal interactions important for metabolic reprogramming in
cancer cells.EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in the Extended Experimental
Procedures. All experimental procedures performed on mice were approved
by the UCSF Institutional Animal Care and Use Committees.Magnetic Resonance Data Acquisition and Processing
One-dimensional 1H MR spectra acquisition was performed on the aqueous
fraction of freshly isolated B cell extracts described in the Extended Experi-
mental Procedures using a 600 MHz Bruker spectrometer equipped with a
cryogenically cooled probe. A 90 pulse and 4 s relaxation delay were used,
and the water resonance was suppressed using excitation sculpting (Hwang
and Shaka, 1995).
All magnetic resonance spectroscopy (MRS) data sets were processed
using NMRLab in the MATLAB programming environment (The MathWorks)
(Gu¨nther et al., 2000). Following standard processing steps, selected signals
arising from residual solvents and from trimethylsilyl propanoic acid were
excluded, and spectra were normalized according to the probabilistic quotient
method (Dieterle et al., 2006). For all data sets, MRS resonances of metabo-
lites were assigned by comparison with spectra of standard compounds (Lud-
wig et al., 2011). Peak integrals of selected metabolites were calculated
using ACD/Spec Manager (v. 9.15) software (Advanced Chemistry Develop-
ment) and normalized to the mean of WT samples for relative quantification.
Statistical significance was determined using a Student’s t test with p < 0.05
considered significant (n = 8/genotype).Metabolic Flux Experiments Using [14C] Formate and [8-14C]
Hypoxanthine
Metabolic labeling experiments were performed as described (Boss and Erbe,
1982; White et al., 1975), with further details provided in the Extended Exper-
imental Procedures. [14C] formate and [8-14C] hypoxanthine were from Amer-
ican Radiolabeled Chemicals (#ARC 0163A and #ARC 0364, respectively).Cells and Delays Myc-Dependent Tumor Initiation and Maintenance
formedmouse embryo fibroblasts treated as specified. Twenty-four hour wash
tosis was measured after 48 hr. Data in graph represent percent increase in the
d cells relative to control siRNA-transfected cells.
amino acid substitution alleles detecting the indicated nucleotide biosynthesis
ubjected to Annexin V/PI FACS analysis.
almitoylated GFP (pGFP) expressing retrovirus coexpressing either control or
V and PI.
yc/+-derived hematopoietic stem cells harboring dox-inducible Prps2 shRNA.
hocytes prepared from mice treated as in (F).
h palmitoylated-GFP-expressing retrovirus that coexpress doxycycline (dox)-
iated syngeneic mice. Survival curves measure days free of palpable lymph
duced with pGFP-expressing dox-inducible Prps2 shRNA, and subsequently
en andmonitor the time to sacrifice of tumor-bearing mice. For (B), (D), and (E),
A or shRNA relative to control siRNA- or shRNA-transduced cells.
3 for (G). **p < 0.01, *p < 0.05, ns, not significant by Student’s t test. See also
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Sucrose Gradient Fractionation and Polysome Profiling
Sucrose gradient fractionation and polysome profiling were performed
as described (Hsieh et al., 2012). Upon polysome fractionation, RNA
was extracted and purified using Trizol reagent and PureLink RNA isolation
kits (Invitrogen). RNA isolated from each fraction was reverse transcribed,
and quantitative real-time PCR analysis of polysomal fractions was performed
using primers listed in the Extended Experimental Procedures. Data are
normalized to 5S rRNA expression and subsequently expressed as a fraction
of total mRNA for either Prps1 or Prps2.
Luciferase Reporter Assays
NIH 3T3 cells were transfected with Prps2 or Prps1 50 UTR pGL3 promoter
plasmids in presence of DN-4EBP1 pMSCV hygro or empty vector control in
six-well dishes using lipofectamine (Invitrogen). Twenty-four hours posttrans-
fection, cells were harvested and lysed in passive lysis buffer (Promega), and
luciferase assays were performed using a Promega Glomax instrument as
described previously (Hsieh et al., 2012).
Fetal Liver Hematopoietic StemCell Culture, Retroviral Preparation,
Infection, and Transplantation
Fetal liver hematopoietic stem cell (HSC) culture, infection, and transplantation
were performed as described with slight variation (Zuber et al., 2011). Retro-
viral constructs used to transduce HSCs with GFP-expressing Tet-PRPS2
shRNA is described in the Extended Experimental Procedures. Efficacy of
infection was assessed by fluorescence-activated cell sorting (FACS) analysis
to determine the percentage of GFP-positive cells. For all transplanted recip-
ient mice, more than 60% of donor HSCs were infected. Tumor-free survival
was monitored twice weekly by palpating lymph nodes. Survival data were
plotted using GraphPad Prism software. p values were calculated using the
log rank test.
Em-Myc/+ Tumor Cell Culture, Infection, Transplantation, and
Monitoring
Em-Myc tumor cells were harvested, cultured, and infected with Tet-PRPS2
shRNAMSCV-pGFP as described (Schmitt et al., 2000). A detailed description
is presented in the Extended Experimental Procedures. After transplantation
via tail vein of 5 3 106 live tumor cells into syngeneic recipients, tumors
were allowed to engraft for several days. Between days 5 and 7 posttransplan-
tation, blood samples from tail bleeds were subjected to FACS analysis to
assay for tumor take bymeasurement of GFP+ B220+ tumor cells. Upon detec-
tion of GFP+ population of circulating B220+ cells, mice were placed in either
vehicle (water) or doxycycline (2 mg/ml in water) treatment regimens repre-
senting day 0 of the survival curve. Survival was monitored daily, and mice
were sacrificed upon becoming moribund or developing tumors >1 cm in
diameter. Survival data were plotted using GraphPad Prism software. p values
were calculated using the log rank test.
Generation of Prps2null Mice and Other Mouse Lines Used
PRPS2tm1a(KOMP)Wtsi embryonic stem (ES) cells used for this research project
were generated by the trans-NIH Knockout Mouse Project (KOMP) and
obtained from the KOMP Repository. PRPS2tm1a(KOMP)Wtsi ES cells contain a
genetrap insertion in the first intron of the PRPS2 gene, which fuses the firstFigure 6. PRPS2 Is Dispensable for Normal Physiology and Cellular Fun
(A) RNA was isolated from purified B cells derived fromWT or Prps2nullmice, and
(B) Western blot (WB) of B cell lysates from mice with indicated genotype.
(C) Spleen weights of 8-week-old WT or Prps2null mice.
(D) Hematoxylin and eosin-stained tissue sections from WT or Prps2null spleens.
(E) The percentage of splenic B220+ cells was assessed by FACS.
(F) Measurement of [14C] formate incorporation into purine nucleotides from prim
(G) WT or Prps2nullMEFs were stably infected with retroviruses encoding the chim
or 250 nM 4-hydroxytamoxifen for 24 hr.
(H–K) Measurement of [14C] formate incorporation into purine nucleotides (H), R
indicated genotypes.
For all graphs, error bars represent SD, ***p < 0.001, **p < 0.01, *p < 0.05, and ns, n
n = 6. nd, not detected. See also Figure S6.40 amino acids of PRPS2 to a b-gal cassette flanked by aSV40polyadenylation
site that acts as a strong transcriptional termination signal. PRPS2tm1a(KOMP)Wtsi
ES cells were propagated by the UCSF ES cell core, and microinjections
of these cells into C57Bl6 albino females were performed by the Gladstone
Institute Transgenic Core Facility to generate chimeric founders. F1 mice
were generated and named Prps2null in the text. A complete list of mouse lines
used in this study is presented in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.03.052.
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